Lana is a results-driven industry executive in the biopharmaceutical field with an entrepreneurial mindset, strong scientific background, and demonstrated success in leading R&D teams in the complex and high-paced healthcare industry. She brings over 20 years of pharmaceutical development experience that spans the full life cycle of therapeutic product development from discovery through to commercialization.
Most recently, Lana worked at QLT Inc. in Vancouver (now Novelion Therapeutics Inc.), where she held positions of increasing responsibility, and was a member of the executive management team for over 10 years. She most recently served as Senior Vice President, Intellectual Property and Technology Development and Chief Patent Officer, with leadership and oversight responsibilities for all R&D aspects of Novelion’s late stage ophthalmology orphan assets. Lana also has extensive experience in negotiating licensing, co-development, merger, acquisition, divestiture, and joint development transactions, and has conducted and lead extensive clinical diligence investigations into numerous technologies, devices and companies in the biotech/medical device space spanning numerous therapeutic areas.
Prior to joining QLT, Dr. Janes worked for several years as a registered patent agent (Canada and the US) in the Toronto offices of Blake, Cassels & Graydon LLP, and Ogilvy Renault LLP (now Norton Rose Fulbright), and has also served as an in-house patent agent at F. Hoffmann-La Roche in Basel, Switzerland, where her practice focused on the strategic development and protection of IP portfolios in the fields of pharmaceutical and biological products.
Lana also currently acts as Chief Operating Officer for the Seattle based biotech company, Retinagenix LLC, a privately held, clinical stage company committed to the development and commercialization of small molecule synthetic chromophore technologies discovered at the University of Washington for the treatment of progressive retinal diseases, and sits on the Boards of Directors for several entrepreneurial start-up biotechs in Vancouver, providing her with valuable experience and insight in strategically and cost-effectively advancing pre-IND stage and semi-virtual companies.
Lana received her AB in Chemistry with honours from Harvard University and her Ph.D. in organic chemistry with honours from McGill University, where she also conducted post-Doctoral work in the field of biological organic chemistry. She is an author of numerous scientific publications in the field of organic and medical chemistry and worked for several years as a synthetic organic chemist in the chemical and food industries in the US and UK.